low - Clinical-stage biotech operations are largely insulated from GDP fluctuations. R&D spending continues regardless of economic conditions, and rare disease drug demand is non-discretionary. However, macro conditions affect: (1) equity financing availability and valuation multiples, (2) M&A activity from strategic acquirers, (3) healthcare budget pressures that could impact future reimbursement, though orphan drugs typically maintain pricing power.

Rising rates negatively impact valuation through higher discount rates applied to distant cash flows (product launch likely 2028+). Pre-revenue biotechs are duration assets - their value derives entirely from discounted future earnings, making them highly sensitive to risk-free rate changes. Higher rates also increase cost of capital for equity raises and reduce appetite for speculative growth assets. Conversely, falling rates expand valuation multiples and improve financing conditions.

growth/speculative - Attracts biotech-focused growth investors and event-driven funds betting on binary clinical/regulatory catalysts. The 100%+ one-year return reflects momentum/speculation around clinical progress. High-risk/high-reward profile appeals to investors comfortable with binary outcomes and multi-year hold periods. Not suitable for value or income investors given negative cash flows and no dividend potential.